Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Drug toxicity: Drug–Drug Interaction

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...

Pharmacokinetics: Drug–Drug Interactions

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...

Drug Toxicity: Risk factors

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Methods of Calculating Low-Density Lipoprotein Cholesterol Level.

JAMA cardiology·2020

Same author

Clinical Lipidology and the Prevention of Vascular Disease: Time for Personalized Therapy.

Clinical pharmacology and therapeutics·2018

Same author

Roundtable discussion: Familial chylomicronemia syndrome: Diagnosis and management.

Journal of clinical lipidology·2018

Same author

Roundtable on etiology of familial chylomicronemia syndrome.

Journal of clinical lipidology·2018

Same author

What is sufficient drug therapy for lipoprotein elevations?

Journal of clinical lipidology·2017

Same author

Genetic effects on efficacy of lipid-lowering drugs.

Journal of clinical lipidology·2017

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Safety of statins.

William Virgil Brown¹

¹Charles Howard Candler Professor of Medicine, Emory University School of Medicine, Atlanta VAMC, Decatur, GA 30033, USA.

Current Opinion in Lipidology

|October 30, 2008

Summary

Statins are highly effective for preventing vascular disease, with serious adverse effects like rhabdomyolysis being rare. Careful patient screening minimizes risks, making the benefits of statin therapy outweigh potential harms.

Area of Science:

Cardiovascular Medicine
Pharmacology
Clinical Therapeutics

Background:

Statins are widely prescribed for hypercholesterolemia.
Extensive clinical trials and two decades of use provide substantial data on statin therapy.

Purpose of the Study:

To review the evidence regarding adverse effects associated with statin use.
To evaluate the safety profile of statin medications.

Main Methods:

Systematic review of clinical trials and prescription data.
Analysis of reported adverse events, focusing on muscle damage, liver function, and other potential side effects.

Main Results:

Rhabdomyolysis is the only significant, well-documented adverse effect, occurring rarely with careful patient selection and monitoring.

Related Experiment Videos

Last Updated: Jun 28, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Elevated liver enzymes (1-3% of patients) are typically benign and transient, without evidence of liver damage.

Other reported effects like myalgias, proteinuria, and peripheral neuropathy are uncommon or not consistently supported by evidence.

Conclusions:

Statins significantly reduce the incidence of myocardial infarction, stroke, and other vascular events.
Adverse event rates are low, and the benefit-risk ratio for statin therapy is highly favorable.
Careful screening for drug interactions and liver function is crucial for safe statin use.